Floatz logo

Ipilimumab

Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

7 Hills Pharma, LLCmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Anaplastic Lymphoma Kinase Genomic Tumor Aberrations cohort.

Asset / SponsorPhaseRating
Nivolumab
7 Hills Pharma, LLC
Phase 1/2CCC
Alintegimod
7 Hills Pharma, LLC
Phase 1/2CCC

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →